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Abstract
Rationale: To prevent or combat infection, increasing the effectiveness of the immune response is highly desirable,
especially in case of compromised immune system function. However, immunostimulatory therapies are scarce, expensive,
and often have unwanted side-effects. b-glucans have been shown to exert immunostimulatory effects in vitro and in vivo in
experimental animal models. Oral b-glucan is inexpensive and well-tolerated, and therefore may represent a promising
immunostimulatory compound for human use.
Methods: We performed a randomized open-label intervention pilot-study in 15 healthy male volunteers. Subjects were
randomized to either the b -glucan (n = 10) or the control group (n = 5). Subjects in the b-glucan group ingested b-glucan
1000 mg once daily for 7 days. Blood was sampled at various time-points to determine b-glucan serum levels, perform ex
vivo stimulation of leukocytes, and analyze microbicidal activity.
Results: b-glucan was barely detectable in serum of volunteers at all time-points. Furthermore, neither cytokine production
nor microbicidal activity of leukocytes were affected by orally administered b-glucan.
Conclusion: The present study does not support the use of oral b-glucan to enhance innate immune responses in humans.
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Introduction
Defense mechanisms against invading pathogens are of vital
importance to our survival. Therefore, to prevent or combat
infection, increasing the effectiveness of the immune response is
highly desirable. However, immunostimulatory therapies are
scarce, expensive, and often have unwanted side-effects [1].
‘‘Medicinal’’ mushrooms are used in alternative medicine
throughout the world for their presumed enhancing effect on the
immune system [2,3]. Although a number of fungal components
have been implicated in these properties, b-glucans (naturally
occurring carbohydrates) have attracted the most attention [4].
Since the early 1900s, numerous in vitro and animal studies have
demonstrated immunostimulatory effects of b-glucans [5]. In
addition, the advent of molecular immunology has provided
rigorous mechanistic explanations for how humans recognize
glucans and how this may influence the immune system [6]. b-
glucan is already applied as a food additive in animal feed to
enhance the immune response [7] and it is also widely offered on
the internet as a dietary supplement for humans, advertised to
have beneficial immunostimulatory effects. Due to the fact that it is
inexpensive and well tolerated, oral b-glucan appears as a
promising candidate to enhance the immune response. However,
there are no studies to substantiate the putative immunostimula-
tory effects of orally administered b-glucan in humans. The only
evidence of immunological effects of oral b-glucan in humans to
date is derived from a study in patients with advanced breast
cancer, in which oral b-glucans enhanced expression of surface
molecules associated with macrophage proliferation and activation
in peripheral blood mononuclear cells (PBMCs) [8].
In the present study we investigated the effects of a commer-
cially available orally administered water-insoluble b-glucan on
immune responses of ex vivo-stimulated leukocytes in healthy
volunteers.
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Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1 in the online supplement.
Subjects
This study was registered at ClinicalTrials.gov as
NCT01727895. After approval from the local Ethics Committee
of the Radboud University Nijmegen Medical Centre, 15 healthy
male volunteers gave written informed consent to participate in
the experiments which took place from May 2013 until July 2013
(Figure 1). All experiments were in accordance with the declara-
tion of Helsinki. Subjects were screened before the start of the
experiment. Subjects with febrile illness during the two weeks
before the experiment were excluded, and subjects were not
allowed to take any prescription drugs. Throughout the study
period, subjects documented their consumption of b-glucan-
containing foods in a ‘‘food-diary’’, and the amount of consumed
b-glucan-containing foods was limited in order to minimize the
inter-individual variability.
Study design
We performed an open-label, intervention pilot-study in 15
healthy human volunteers. The study design is depicted in
Figure 2. Briefly, subjects were randomized to either the b-glucan
group (n= 10) or the control group (n= 5) using the sealed
envelope method. Subjects in the b-glucan group ingested b-
glucan (water-insoluble b-glucan derived from bakers yeast [S.
cerevisiae] sold as a dietary supplement [Glucan #300, BG;
Biothera, Eagan, Minnesota, USA, for Transferpoint, Columbia,
USA, hereafter designated as BG]) 1000 mg once daily as
recommended by the manufacturer, for 7 days. This preparation,
has a purity of at least 83% guaranteed by the manufacturer.
Before the first BG ingestion (on day 0) as well as 3, 6, and
24 hours afterwards, subjects came to the hospital for blood
sampling and reporting of side-effects. This sampling schedule was
repeated on day 6 (before and after the seventh BG ingestion). A
final single sampling time-point took place on day 20. The subjects
in the control group (n = 5) did not take BG, but the sampling
schedule was otherwise identical.
Cytokine measurements
Venous blood was drawn into EDTA tubes, after which
peripheral blood mononuclear cells (PBMCs) were isolated as
described previously [9]. In short, blood was diluted in phosphate
buffered saline (PBS) (1:1) and fractions were separated by Ficoll
(Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) density
gradient centrifugation. Cells were washed twice with PBS and
resuspended in RPMI-1640+ (RPMI-1640 Dutch modification
supplemented with 10 mg/mL gentamicin, 10 mM L-glutamine,
and 10 mM pyruvate) (Gibco, Invitrogen, Breda, The Nether-
lands). PBMCs were counted using a particle counter (Beckmann
Coulter, Woerden, The Netherlands) and were plated in 96 well
round-bottom plates (Corning, NY, USA) at a final concentration
of 2.56106/mL, in a total volume of 200 mL. The PBMCs were
stimulated for 24 hours, 48 hours, and 7 days with medium alone,
or medium containing E. coli lipopolysaccharide (LPS; 10 ng/mL),
heat-inactivated Candida albicans blastoconidia UC820 (16106
microorgansims/mL), Pam3Cys 10 mg/mL (EMC Microcollec-
tions), sonicated mycobacterium tuberculosis (MTB) H37Rv (1 mg/
mL), poly(I:C) 50 mg/mL (Invivogen), S. aureus (16107 micro-
organsims/mL), antiCD3/antiCD28 2,56105 beads/well (Miltenyi
Biotec). After stimulation, cell culture supernatant was collected and
stored at 220uC. When all samples were collected, cytokines were
measured using commercially available ELISAs (R&D Systems,
MN, USA and Sanquin, Amsterdam, The Netherlands) according
to the protocols supplied by the manufacturer.
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0108794.g001
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Microbicidal activity assay
Microbicidal activity assay was performed as previously
described, using the fungal microorganism Candida albicans as a
model pathogen [10]. Briefly, C. albicans UC820 yeast suspension
was incubated with PBMCs isolated from the volunteers at day 0
(t = 0) and day 6 (t = 0) at a MOI of 1:5 or 1:50 in RPMI in a 96
wells plate. C. albicans UC820 suspension was obtained from an
overnight culture in 25 ml liquid Sabouraud at 29uC. The C.
albicans solution was washed three times with PBS, and the
number of yeast cells counted in a hemacytometer. C. albicans
were then incubated with PBMCs or no cells (control well) for
5 hours at 37uC. The amount of C. albicans added to the wells was
determined by plating serial dilutions on Sabouraud plates in
duplo. After a 5–hour incubation, the content of each well was
recovered in sterile water and serially diluted. Serial dilutions were
plated on Sabouraud plates in duplo. After 24 hours at 29uC, the
CFU were counted. The candidacidal activity was calculated as a
ratio of Candida growth with PBMCs vs. control wells (Candida
alone, no cells).
(1R3)-b-D-glucan detection in serum samples
b-glucan levels were determined for all subjects on several time
points using the Fungitell kit (Associates of Cape Cod, Inc., Cape
Cod, MA), according to the manufacturer’s instructions [11].
Lower and upper detection limits were 31.25 and 500 pg/ml,
respectively.
Calculations and statistical analysis
Distribution of data was determined using Kolmogorov-
Smirnov tests. Demographic data were analyzed using Mann-
Whitney U tests. Comparisons between the two groups over time
were made using repeated measures two-way analysis of variance
(ANOVA, interaction term). Ex vivo stimulation cytokine data
were log-transformed to obtain a normal distribution. A p-value of
,0.05 was considered statistically significant. Calculations and
statistical analyses were performed using Graphpad Prism version
5.0 (Graphpad Software, San Diego, CA, USA).
Results
Demographic characteristics
Demographic characteristics of the study population are listed
in Table 1. There were no significant differences in baseline
characteristics between the two study groups. No serious adverse
events occurred during the trial. BG intake was well tolerated, with
no side effects reported besides one subject who reported a flare of
acne one week after discontinuation of BG for which he contacted
his general practitioner.
(1R3)-b-D-glucan serum levels
Following oral administration, b-glucan was barely detectable in
serum of volunteers at all time-points, and this was not significantly
different from the b-glucan levels observed in the placebo group
(data not shown).
Cytokine production by ex vivo-stimulated PBMCs
The production of the archetypal proinflammatory cytokine
tumor necrosis factor (TNF)-a after incubation with various stimuli
at different time points showed considerable interindividual
variation, but it was not affected by b-glucan intake (Figure 3).
Furthermore, no relevant differences in TNF-a production
compared with the control group were observed. Likewise, no
effects of BG intake within the b-glucan group or between the b-
glucan group and the control group were observed with regard to
the production of interleukin (IL)-6, IL-1b, IL-10, Interferon
Figure 2. Experimental design of the study. The primary outcome measure was the TNF-a secretion by ex vivo lipopolysaccharide (LPS) -
stimulated peripheral blood mononuclear cells (PBMC’s). Secondary endpoints were the production of other cytokines (TNF-a, IL-6, IL-10, IL-1b, IL-17,
IL-22, Interferon (IFN)-c) by leukocytes ex vivo stimulated with various stimuli, b-glucan plasma levels, and Microbicidal activity of PBMC’s.
doi:10.1371/journal.pone.0108794.g002
Table 1. Demographic characteristics.
b-glucan (n =10) Control (n =5) p-value
Age (years) 20 [19–22] 20 [19–24] 1.00
Hight (cm) 182 [179–188] 183 [177–196] 0.78
Weight (kg) 81 [74–87] 80 [74–87] 0.90
BMI (kg/m2) 24.1 [22.9–26.5] 23.9 [23.6–25.1] 0.95
BMI: body mass index. Data are presented as median and interquartile range. p-values calculated using Mann-Whitney U-tests.
doi:10.1371/journal.pone.0108794.t001
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Figure 3. Effect of oral b-glucan on ex vivo TNF-a production by PBMCs stimulated for 24 hours with lipopolysaccharide (LPS),
Pam3Cys, Poly(I:C), S. aureus, C. albicans, or M. tuberculosis (MTB). To correct for possible baseline differences between groups, concentrations
at day 0 are set at 1, and concentrations at subsequent time-points are plotted as ratios (median and interquartile range). Baseline (day 0) TNF-a
Immunological Effects of Oral Beta-Glucan
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(IFN)-c, IL-17 and IL-22 (Figure S1, Panel A–D, in the online
supplement).
Microbicidal activity
We assessed the candidacidal properties of PBMCs isolated
from volunteers before and 6 days after the administration of b-
glucan, and at the same time-points in the control group. No
significant differences could be observed in candidacidal activity in
both groups, using multiplicity of infection (MOI) of either 1:50 or
1:5 (Figure 4).
Discussion
In the present study, we show that daily intake of 1000 mg
commercially available oral b-glucan for 7 days does not result in
detectable serum b-glucan levels in healthy human volunteers, and
that it does not modulate the innate immune response, as reflected
by leukocyte-derived cytokine production upon ex vivo stimulation
and microbicidal activity.
Because of increasing evidence for immunomodulatory proper-
ties of b-glucans [5,10], and because commercially available oral
b-glucans are widely advertised as having beneficial immunosti-
mulatory effects, we wanted to assess their biological effects in
humans. b-glucans are glucose polymers which can be isolated
from cell walls of yeasts and mushrooms, but also from cell walls of
other fungi, bacteria, algae, and cereal grains [5]. Their activity
has been shown to be influenced by their degree of branching, size,
molecular structure [12,13], and the purity of the administered b-
glucan [12]. The most active b-glucans reportedly share a
common structure: a main chain consisting of (l-3)-linked b-D
glucopyranosyl units, along which are randomly dispersed single
b-D-glucopyranosyl units attached by l-6 or 1-4 linkages [5]. The
BG used in this study is a polymer of b-(1-3)-D-glycopyranosyl
units with branching at b-(1-6)-D-glycopyranosyl units, therefore
belonging to the class of most active b-glucans. In addition, in an
evaluation of four different orally administered commercially
available b-glucans in mice, BG was shown to be the most potent
in increasing phagocytosis capacity of peripheral blood cells and
IL-2 production of splenic cells [10]. Based on these data, and
because BG is rated ‘GRAS’ (Generally Recognized As Safe) by
the Food and Drug Administration (FDA) as a dietary food
additive supplement [14], and safe and non-toxic by the Dutch
Medicines Evaluation Board (MEB) [15], we deemed this
preparation of BG representative of commercially available oral
b-glucans. Because of the complete absence of any effect on
cytokine production or microbicidal activity, although investigated
in a small number of subjects for only a limited period, we
conclude that BG or similar glucan products do not appear to be
viable approaches for immunostimulation in humans.
The lack of immunostimulatory effects of b-glucan in our study
could have several reasons. First, it could be due to the absence of
adequate absorption of b-glucans from the intestinal tract in
healthy volunteers, which is in agreement with the undetectable
serum levels found in various other studies showing that enteral
administration of insoluble b-glucans from different sources result
in low systemic blood levels (less than 0.5%) in mice [16], and
weaned pigs [17]. Nevertheless, despite these low systemic blood
levels, significant systemic immunomodulating effects in terms of
humoral and cellular immune responses were demonstrated. It
was speculated that these effects are exerted by enterocytes that
facilitate the transportation of b-glucans and similar compounds
across the intestinal cell wall into the lymph fluid, where they
interact with macrophages and thereby activate the immune
system despite low serum levels [18]. Given the lack of effects of
BG in our study, it is unlikely that these local effects also take place
to a significant degree in humans.
A second explanation might be related to the water solubility of
b-glucans, because previous studies have demonstrated that water
soluble b-glucans interact with the immune system differently
compared with their insoluble counterparts. Soluble b-glucans
activate the immune system in a complement mediated manner,
depending on specific antibodies[19], while insoluble b-glucans,
like BG used in this study, activate both the innate and the
adaptive immune responses via the dectin-1 receptor pathway
[19,20]. As such, it has been suggested that soluble b-glucans
possess less biological activity than their insoluble counterparts.
Therefore, although we did not investigate a soluble formula, it is
unlikely that orally administered water soluble b-glucans will have
a more pronounced immunostimulatory effect in humans than the
concentrations in pg/ml [interquartile range] of subjects in the b-glucan and control groups were: LPS: 691 [276–2649] and 749 [287–1160]),
Pam3Cys: 855 [590–1727] and 1242 [622–3567], Poly(I:C): 107 [78–399] and 125 [78–250], S. aureus: 21948 [14347–41751] and 19424 [12140–31722], C.
albicans: 10875 [5860–14159] and 6208 [3924–14943], and MTB: 424 [285–1980] and 1153 [218–2461]. P values between groups were calculated
using repeated measures two-way analysis of variance (ANOVA, interaction term) on log transformed data.
doi:10.1371/journal.pone.0108794.g003
Figure 4. Microbicidal activity of PBMCs isolated from the
volunteers at day 0 (before b-glucans intake), or at day 6 (after
six days of b-glucan intake) from b-glucan (white) or from
control (grey) volunteers. The microbicidal activity was calculated as
a ratio of Candida growth with PBMCs vs. control wells (Candida alone,
no cells). Data are presented as mean 6 SEM. P values between groups
were calculated using repeated measures two-way analysis of variance
(ANOVA, interaction term).
doi:10.1371/journal.pone.0108794.g004
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BG used in this study. However, future studies are warranted to
assess this aspect.
Third, the lack of effects might be related to the fact we used a
commercially available b-glucan preparation sold as a dietary
supplement, with a relatively modest purity of at least 83%. It is
possible that a highly purified pharmaceutical preparation
optimized for oral delivery could have immunostimulatory effects
in humans. Finally, we only investigated one dose of BG, based on
the recommendation of the manufacturer, which is not supported
by empirical data. Nevertheless, this dose is similar to that used in
two previous studies, where it was demonstrated that oral ingestion
of 900 mg water-insoluble b-glucan daily for 16 or 26 weeks
reduced the incidence in common cold episodes during the cold
season [21,22]. Of note, endpoints in both studies were based on
questionaires, no immunological endpoints were assessed. Also,
the dose used in the present study is higher than the dose rated
‘GRAS’ by the FDA and MEB (375 mg per day) [14] [15], which
was based on the mean background intake of b-glucans from other
dietary sources.
While our study does not support use of oral b-glucan to
enhance the immune response, it does not exclude that parental
administration of b-glucan, as currently performed in clinical trials
(e.g. NCT01269385, NCT00002099), could represent a valuable
immunostimulatory therapy. It has been reported that b-glucan
from S. cerevisiae administered intravenously to high-risk surgical
patients resulted in decreased infection incidence, reduced need
for antibiotics, shortened intensive care unit length stay, and
ultimately improved survival compared with placebo [23]. In
addition, several clinical trials in East Asia have proposed
immunomodulatory and antioncogenic effects of b-glucan in
cancer patients [24–26]. Larger studies are warranted to confirm
these data, investigate the biological mechanisms though which
effects are induced, and to fully explore the therapeutic potential of
b-glucans.
Conclusion
Despite promising results obtained in in vitro and animal
studies, our study demonstrates that the use of oral b-glucan does
not enhance the responsiveness of the immune system in humans.
Future efforts should concentrate on assessing the immunological
and clinical effects of intravenous b-glucan preparations.
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